{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:02:05Z","timestamp":1791118925666,"version":"4.1.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.pharmthera.2014.05.004","type":"journal-article","created":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T20:46:59Z","timestamp":1400100419000},"page":"50-59","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Role for the nicotinic cholinergic system in movement disorders; therapeutic implications"],"prefix":"10.1016","volume":"144","author":[{"given":"Maryka","family":"Quik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiomara A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Bordia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2014.05.004_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0020","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1111\/j.1460-9568.1997.tb01702.x","article-title":"Choline is a selective agonist of alpha7 nicotinic acetylcholine receptors in the rat brain neurons","volume":"9","author":"Alkondon","year":"1997","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0010","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/j.1530-0277.2006.00143.x","article-title":"Behavioral interaction between nicotine and ethanol: possible modulation by mouse cerebellar glutamate","volume":"30","author":"Al-Rejaie","year":"2006","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0025","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.bcp.2009.06.024","article-title":"Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination","volume":"78","author":"Anderson","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0030","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00213-011-2393-2","article-title":"Efficacy and safety of the novel alpha(4)beta (2) neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit\/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study","volume":"219","author":"Apostol","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/npp.2012.194","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of alpha4beta2 agonist ABT-894 in adults with ADHD","volume":"38","author":"Bain","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0091-3057(97)00537-6","article-title":"Sensitization of the mesoaccumbens dopamine response to nicotine","volume":"59","author":"Balfour","year":"1998","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0045","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1476-5381.1992.tb09067.x","article-title":"The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity","volume":"105","author":"Benwell","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0050","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/mds.25366","article-title":"Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2012.651457","article-title":"New pharmacological avenues for the treatment of l-dopa-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors","volume":"21","author":"Blandini","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0060","first-page":"1568","article-title":"Use of choline in the treatment of ataxia associated with multiple sclerosis","volume":"121","author":"Blattel","year":"1979","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.108.140897","article-title":"Continuous and intermittent nicotine treatment reduces l-3,4-dihydroxyphenylalanine (l-dopa)-induced dyskinesias in a rat model of Parkinson's disease","volume":"327","author":"Bordia","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0070","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.109.162396","article-title":"Nicotinic receptor-mediated reduction in l-dopa-induced dyskinesias may occur via desensitization","volume":"333","author":"Bordia","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0075","first-page":"32.07","article-title":"Varenicline markedly decreases antipsychotic-induced tardive dyskinesia in a rodent model","volume":"33","author":"Bordia","year":"2013","journal-title":"Soc Neurosci Abstr"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0080","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1124\/jpet.112.194852","article-title":"Varenicline is a potent partial agonist at alpha6beta2* nicotinic acetylcholine receptors in rat and monkey striatum","volume":"342","author":"Bordia","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0085","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/jpet.111.189100","article-title":"Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats","volume":"340","author":"Bordia","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-381328-2.00005-5","article-title":"New approaches to therapy","volume":"98","author":"Brotchie","year":"2011","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0095","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/jpet.108.145292","article-title":"Desensitization of nicotinic acetylcholine receptors as a strategy for drug development","volume":"328","author":"Buccafusco","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0100","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.tins.2007.03.005","article-title":"Dopamine dysregulation of movement control in l-dopa-induced dyskinesia","volume":"30","author":"Cenci","year":"2007","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0105","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"l-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.010909.105741","article-title":"Allosteric receptors: from electric organ to cognition","volume":"50","author":"Changeux","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0115","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0006-2952(90)90436-O","article-title":"Dopaminergic mechanisms in the locomotor stimulant effects of nicotine","volume":"40","author":"Clarke","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0120","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation","volume":"48","author":"Coe","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0125","first-page":"2218","article-title":"A randomized trial of varenicline (chantix) for the treatment of spinocerebellar ataxia type 3","volume":"79","author":"Connolly","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0135","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","article-title":"Tardive dyskinesia and new antipsychotics","volume":"21","author":"Correll","year":"2008","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0145","doi-asserted-by":"crossref","first-page":"9574","DOI":"10.1523\/JNEUROSCI.1196-12.2012","article-title":"Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei","volume":"32","author":"Creed","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bbr.2011.01.025","article-title":"Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats","volume":"219","author":"Creed-Carson","year":"2011","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0022-3565(24)37015-6","article-title":"ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys","volume":"283","author":"Decker","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-008-1135-6","article-title":"Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-dopa-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat","volume":"199","author":"Dupre","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1054\/mehy.1997.0623","article-title":"Smoking, nicotine and psychiatric disorders: evidence for therapeutic role, controversies and implications for future research","volume":"52","author":"Dursun","year":"1999","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0165","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(94)90388-3","article-title":"Longlasting improvement of Tourette's syndrome with transdermal nicotine","volume":"344","author":"Dursun","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0170","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease","volume":"26","author":"Duty","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0175","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0180","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0024-3205(99)00040-5","article-title":"Potentiation of haloperidol catalepsy by microinjections of nicotine into the striatum or pons in rats","volume":"64","author":"Elazar","year":"1999","journal-title":"Life Sci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0185","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0091-3057(91)90256-2","article-title":"Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity","volume":"38","author":"Emerich","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0190","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s40265-013-0105-4","article-title":"Non-dopaminergic treatments for motor control in Parkinson's disease","volume":"73","author":"Fox","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0195","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/mds.22473","article-title":"Serotonin and Parkinson's disease: on movement, mood, and madness","volume":"24","author":"Fox","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0200","first-page":"196028","article-title":"Metabotropic glutamate receptors for Parkinson's disease therapy","volume":"2013","author":"Gasparini","year":"2013","journal-title":"Park Dis"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0205","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/B978-0-444-52014-2.00042-2","article-title":"Typical and atypical neuroleptics","volume":"100","author":"Gershanik","year":"2011","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tins.2005.04.009","article-title":"Desensitization of nicotinic ACh receptors: shaping cholinergic signaling","volume":"28","author":"Giniatullin","year":"2005","journal-title":"Trends Neurosci"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2014.05.004_bb0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/jnc.12303","article-title":"Mitochondrial pathophysiology in Friedreich's ataxia","volume":"126","author":"Gonzalez-Cabo","year":"2013","journal-title":"J Neurochem"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0220","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1460-9568.2005.04196.x","article-title":"Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning","volume":"22","author":"Guigoni","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"310","author":"Hill","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0235","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuropharm.2010.12.032","article-title":"Nicotinic receptor agonists decrease l-dopa-induced dyskinesias most effectively in moderately lesioned parkinsonian rats","volume":"60","author":"Huang","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0230","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.111.182949","article-title":"Nicotine reduces l-dopa-induced dyskinesias by acting at {beta}2 nicotinic receptors","volume":"338","author":"Huang","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0240","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/pr.111.005678","article-title":"The pharmacology of l-dopa-induced dyskinesia in Parkinson's disease","volume":"65","author":"Huot","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0245","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/jpet.112.198085","article-title":"Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain","volume":"343","author":"Hussmann","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2012.03.023","article-title":"Animal models of l-dopa-induced dyskinesia: an update on the current options","volume":"211","author":"Iderberg","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0255","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.expneurol.2013.09.003","article-title":"Modulating mGluR5 and 5-HT1A\/1B receptors to treat l-dopa-induced dyskinesia: effects of combined treatment and possible mechanisms of action","volume":"250","author":"Iderberg","year":"2013","journal-title":"Exp Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2014.05.004_bb0260","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1353-8020(11)70038-4","article-title":"Striatal plasticity in Parkinson's disease and l-dopa induced dyskinesia","volume":"18","author":"Iravani","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0265","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/ana.21489","article-title":"Functional models of Parkinson's disease: a valuable tool in the development of novel therapies","volume":"64","author":"Jenner","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0270","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1021\/jm070755h","article-title":"Synthesis and structure\u2013activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel alpha4beta2 nicotinic acetylcholine receptor selective agonists","volume":"50","author":"Ji","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0275","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuropharm.2013.06.005","article-title":"TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-dopa-induced dyskinesia in the MPTP macaque","volume":"73","author":"Johnston","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0280","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1212\/WNL.27.1.70","article-title":"Physostigmine in familial ataxias","volume":"27","author":"Kark","year":"1977","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0285","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.31.3.288","article-title":"Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxias","volume":"31","author":"Kark","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0290","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/mds.23867","article-title":"Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease","volume":"26","author":"Kobylecki","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0295","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/NEN.0b013e31827e5762","article-title":"Friedreich ataxia: neuropathology revised","volume":"72","author":"Koeppen","year":"2013","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0300","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1136\/bmj.2.6149.1403-a","article-title":"Oral choline in cerebellar ataxia","volume":"2","author":"Legg","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0305","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0022-510X(81)90162-3","article-title":"Choline chloride in the treatment of cerebellar and spinocerebellar ataxia","volume":"50","author":"Livingstone","year":"1981","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0310","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.111.185306","article-title":"Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor","volume":"339","author":"Lummis","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0315","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.18553\/jmcp.2012.18.S5-B.1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics","volume":"18","author":"Maher","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0320","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bcp.2009.05.022","article-title":"Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain","volume":"78","author":"Marks","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0325","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00213-010-2028-z","article-title":"Desensitization of delta-opioid receptors in nucleus accumbens during nicotine withdrawal","volume":"213","author":"McCarthy","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0330","first-page":"793","article-title":"Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder","volume":"148","author":"McConville","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0335","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0340","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0006-3223(91)90163-G","article-title":"Smoking and movement disorders in psychiatric patients","volume":"30","author":"Menza","year":"1991","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0345","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0350","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuropharm.2008.07.041","article-title":"Diversity of vertebrate nicotinic acetylcholine receptors","volume":"56","author":"Millar","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0355","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0014-2999(01)01284-5","article-title":"Effect of 5-HT1A and 5-HT2A\/2C receptor modulation on neuroleptic-induced vacuous chewing movements","volume":"428","author":"Naidu","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0360","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0006-3223(96)00289-2","article-title":"Cigarette smoking is associated with abnormal involuntary movements in the general male population\u2014a study of men born in 1933","volume":"41","author":"Nilsson","year":"1997","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0365","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm.2165","article-title":"Missing pieces in the Parkinson's disease puzzle","volume":"16","author":"Obeso","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0370","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s002130100733","article-title":"l-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations","volume":"156","author":"Pearce","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0375","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs","volume":"200","author":"Peluso","year":"2012","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0380","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/bmj.2.6190.613","article-title":"Choline in hereditary ataxia","volume":"2","author":"Philcox","year":"1979","journal-title":"Br Med J"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0385","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pneurobio.2007.12.005","article-title":"It is not \u201ceither\/or\u201d: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood","volume":"84","author":"Picciotto","year":"2008","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0390","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2741\/2695","article-title":"Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease","volume":"13","author":"Picciotto","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0395","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1124\/mol.64.3.619","article-title":"l-dopa treatment modulates nicotinic receptors in monkey striatum","volume":"64","author":"Quik","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0400","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuropharm.2013.03.038","article-title":"Alpha4beta2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats","volume":"71","author":"Quik","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0410","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bcp.2013.06.027","article-title":"Multiple CNS nicotinic receptors mediate l-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice","volume":"86","author":"Quik","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0405","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bcp.2013.06.027","article-title":"Multiple CNS nicotinic receptors mediate l-dopa-induced dyskinesias; studies with parkinsonian nicotinic receptor knockout mice","volume":"86","author":"Quik","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0415","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0420","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nbd.2012.09.006","article-title":"Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function","volume":"50","author":"Quik","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0425","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/mds.25594","article-title":"Nicotine reduces established l-dopa-induced dyskinesias in a monkey model of Parkinson's disease","volume":"28","author":"Quik","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0430","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.neuropharm.2012.04.029","article-title":"Role for alpha6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice","volume":"63","author":"Quik","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0435","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mds.25028","article-title":"Nicotine as a potential neuroprotective agent for Parkinson's disease","volume":"27","author":"Quik","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0440","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1523\/JNEUROSCI.21-15-05494.2001","article-title":"Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey","volume":"21","author":"Quik","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0445","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1124\/mol.63.5.1169","article-title":"Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice","volume":"63","author":"Quik","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0450","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/pr.110.003269","article-title":"{Alpha}6{beta}2* and {alpha}4{beta}2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease","volume":"63","author":"Quik","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0455","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2012.02.031","article-title":"Effects of sazetidine-A, a selective alpha4beta2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats","volume":"682","author":"Rezvani","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0460","first-page":"195","article-title":"Action of physostigmine on inherited ataxias","volume":"21","author":"Rodriguez-Budelli","year":"1978","journal-title":"Adv Neurol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0465","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuropharm.2012.05.043","article-title":"Pharmacological treatment of tic disorders and Tourette syndrome","volume":"68","author":"Roessner","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0470","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.tips.2007.05.003","article-title":"Rationale, pharmacology and clinical efficacy of partial agonists of alpha(4)beta(2) nACh receptors for smoking cessation","volume":"28","author":"Rollema","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0475","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1476-5381.2010.00682.x","article-title":"Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence","volume":"160","author":"Rollema","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0480","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.pain.2012.01.009","article-title":"Efficacy and safety of the alpha4beta2 neuronal nicotinic receptor agonist ABT-894 in patients with diabetic peripheral neuropathic pain","volume":"153","author":"Rowbotham","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0485","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pneurobio.2013.01.001","article-title":"Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7","volume":"104","author":"Rub","year":"2013","journal-title":"Prog Neurobiol"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2014.05.004_bb0490","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/S1353-8020(11)70039-6","article-title":"The serotonin system: a potential target for anti-dyskinetic treatments and biomarker discovery","volume":"18","author":"Rylander","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0495","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0500","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.tips.2006.08.002","article-title":"Opioids and motor complications in Parkinson's disease","volume":"27","author":"Samadi","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0505","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0753-3322(89)90186-8","article-title":"Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome","volume":"43","author":"Sanberg","year":"1989","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0510","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0163-7258(96)00199-4","article-title":"Nicotine for the treatment of Tourette's syndrome","volume":"74","author":"Sanberg","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0515","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.physbeh.2012.06.023","article-title":"Translating laboratory discovery to the clinic: from nicotine and mecamylamine to Tourette's, depression, and beyond","volume":"107","author":"Sanberg","year":"2012","journal-title":"Physiol Behav"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0520","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2008.10.005","article-title":"Neurobiology and treatment of Parkinson's disease","volume":"30","author":"Schapira","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0525","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson's disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0530","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3371\/CSRP.4.1.5","article-title":"Dopamine D2 receptors as treatment targets in schizophrenia","volume":"4","author":"Seeman","year":"2010","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0535","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0540","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0006-3223(00)00945-8","article-title":"Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine)","volume":"48","author":"Shytle","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0545","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/00004583-199612000-00015","article-title":"Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome","volume":"35","author":"Silver","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0550","doi-asserted-by":"crossref","first-page":"707","DOI":"10.4088\/JCP.v62n0908","article-title":"Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study","volume":"62","author":"Silver","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0555","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/cap.2000.10.59","article-title":"Mecamylamine in Tourette's syndrome: a two-year retrospective case study","volume":"10","author":"Silver","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0560","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/00004583-200109000-00020","article-title":"Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder","volume":"40","author":"Silver","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0565","first-page":"3","article-title":"Behavioural pharmacology of nicotine: implications for multiple brain nicotinic receptors","volume":"152","author":"Stolerman","year":"1990","journal-title":"Ciba Found Symp"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0570","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)37014-4","article-title":"ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties","volume":"283","author":"Sullivan","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0575","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0580","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuroscience.2008.08.046","article-title":"Attenuation of ethanol-induced ataxia by alpha(4)beta(2) nicotinic acetylcholine receptor subtype in mouse cerebellum: a functional interaction","volume":"157","author":"Taslim","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0585","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1530-0277.2010.01371.x","article-title":"The role of nicotinic acetylcholine receptor (nAChR) alpha7 subtype in the functional interaction between nicotine and ethanol in mouse cerebellum","volume":"35","author":"Taslim","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0590","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/B978-0-12-411546-0.00015-9","article-title":"Emerging treatment strategies in Tourette syndrome: what's in the pipeline?","volume":"112","author":"Termine","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0595","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00702-013-0979-z","article-title":"The pharmacology of Tourette syndrome","volume":"120","author":"Thomas","year":"2013","journal-title":"J Neural Transm"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0600","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ana.1099","article-title":"Levodopa induces dyskinesias in normal squirrel monkeys","volume":"50","author":"Togasaki","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0605","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s00213-002-1259-z","article-title":"The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats","volume":"165","author":"Turrone","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0610","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ene.12341","article-title":"EFNS\/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood","volume":"21","author":"van de Warrenburg","year":"2014","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0615","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuropharm.2013.05.016","article-title":"Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia","volume":"73","author":"Wecker","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0620","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archneur.1997.00550160041013","article-title":"Double-blind crossover study with physostigmine in patients with degenerative cerebellar diseases","volume":"54","author":"Wessel","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0625","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/mds.23695","article-title":"Milestones in research on the pathophysiology of Parkinson's disease","volume":"26","author":"Wichmann","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0630","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2004.12.002","article-title":"Nicotine: from molecular mechanisms to behaviour","volume":"5","author":"Wonnacott","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0635","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0640","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0006-3223(87)90131-4","article-title":"Nicotine exposure and tardive dyskinesia","volume":"22","author":"Yassa","year":"1987","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0645","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.0b013e318247cc7a","article-title":"A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3","volume":"78","author":"Zesiewicz","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0650","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/WNF.0b013e31818736a9","article-title":"Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14)","volume":"31","author":"Zesiewicz","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0655","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0404.2008.01070.x","article-title":"Treatment of imbalance with varenicline Chantix(R): report of a patient with Fragile X tremor\/ataxia syndrome","volume":"119","author":"Zesiewicz","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0660","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CND.0b013e3181910074","article-title":"Subjective improvement in proprioception in 2 patients with atypical Friedreich ataxia treated with varenicline (Chantix)","volume":"10","author":"Zesiewicz","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0695","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mds.25817","article-title":"ABT-089 and ABT-894 reduce l-dopa-induced dyskinesias in a monkey model of Parkinson's disease","volume":"29","author":"Zhang","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0670","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.113.207639","article-title":"Nicotinic receptor agonists reduce l-dopa-induced dyskinesias in a monkey model of Parkinson's disease","volume":"347","author":"Zhang","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0680","doi-asserted-by":"crossref","first-page":"11655","DOI":"10.1523\/JNEUROSCI.0288-13.2013","article-title":"Aberrant restoration of spines and their synapses in l-dopa-induced dyskinesia: involvement of corticostriatal but not thalamostriatal synapses","volume":"33","author":"Zhang","year":"2013","journal-title":"J Neurosci"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0675","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.pnpbp.2011.06.006","article-title":"Smoking and tardive dyskinesia in male patients with chronic schizophrenia","volume":"35","author":"Zhang","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0685","first-page":"141","article-title":"Role of atypical antipsychotics in rapid cycling bipolar disorder: a review of the literature","volume":"23","author":"Zupancic","year":"2011","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.pharmthera.2014.05.004_bb0690","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1124\/mol.108.045104","article-title":"Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors","volume":"73","author":"Zwart","year":"2008","journal-title":"Mol Pharmacol"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725814000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725814000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T22:42:30Z","timestamp":1746225750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725814000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0163725814000990"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2014.05.004","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role for the nicotinic cholinergic system in movement disorders; therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2014.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}